LOGIN  |  REGISTER
Recursion
C4 Therapeutics

LifeWallet Announces it will Cancel and Reschedule its Fourth Quarter and Full Year 2022 Results Earnings Release and Conference Call & will File Form 12B-25

March 30, 2023 | Last Trade: US$1.79 0.12 -6.28

CORAL GABLES, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet” or “LIFW” or the “Company”), announces it will cancel and reschedule its March 31, 2023, fourth quarter and full year 2022 earnings release and investors conference call and in addition will file Form 12b-25 Notification of Late Filing with Securities Exchange Commission. The company is currently negotiating amendments to certain material agreements and evaluating the accounting and related disclosure in Form 10K. Therefore, the company will not file its Annual Report on the Form 10-K for the period ended December 31, 2022, within the prescribed time period without unreasonable effort or expense because management needs additional time to finalize and analyze the disclosure in its Form 10-K. The company currently anticipates that it will file its Form 10-K within the 15-day time period prescribed in Rule 12b-25 promulgated under the Securities Exchange Act of 1934. The Company will make a further announcement in a subsequent press release to schedule the date and time of the earnings conference call.

About LifeWallet

Founded in 2014 as MSP Recovery, LifeWallet has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries from responsible parties. LifeWallet provides comprehensive solutions for multiple industries including healthcare, legal, education, and sports NIL, while innovating technologies to help save lives. For more information, visit: investor.lifewallet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts, including for example expected terms of the purchase, related financing, or sale of claims pursuant to the transactions described herein, which is not finalized and subject to negotiation and related risks. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance or results and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by MSP Recovery herein speaks only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for MSP to predict or identify all such events or how they may affect it. MSP has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, risks associated with the negotiation of the purchase and sale of assets; and those other factors included in MSP’s Quarterly Reports on Form 10-Q or Annual Reports on Form 10-K, and other reports filed by it with the SEC. These statements constitute the Company's cautionary statements under the Private Securities Litigation Reform Act of 1995.

For Media:
ICR, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investors:
ICR, Inc.
Marc Griffin
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB